{"filing":{"accession_number":"0001437749-26-017994","cik":"0000925741","ticker":"BCDA","company_name":"BioCardia, Inc.","form":"8-K","filing_date":"2026-05-21","report_date":null,"primary_document":"bcda20260520_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/925741/000143774926017994/bcda20260520_8k.htm"},"events":[{"id":9488,"run_id":8321,"accession_number":"0001437749-26-017994","anchor_item_number":"7.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"summary":"BioCardia disclosed positive preliminary clinical trial results for CardiAMP Cell Therapy presented at a major medical conference (Euro PCR), showing safety (no major adverse cardiac events) and efficacy outcomes (179-second improvement in exercise tolerance, 82% reduction in angina episodes at six months through two-year follow-up). While this is clinical trial data rather than financial results or a traditional earnings release, the positive efficacy and safety findings for a lead therapeutic candidate are material to investors' assessment of the company's pipeline and commercial prospects. This does not fit neatly into the earnings_release category (which typically refers to financial results) but represents a material clinical milestone disclosure.","company_name":"BioCardia, Inc.","ticker":"BCDA","filing_date":"2026-05-21","form":"8-K","submitted_at":null,"items":[{"id":1142,"accession_number":"0001437749-26-017994","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"BioCardia disclosed positive preliminary clinical trial results for CardiAMP Cell Therapy presented at a major medical conference (Euro PCR), showing safety (no major adverse cardiac events) and efficacy outcomes (179-second improvement in exercise tolerance, 82% reduction in angina episodes at six months through two-year follow-up). While this is clinical trial data rather than financial results or a traditional earnings release, the positive efficacy and safety findings for a lead therapeutic candidate are material to investors' assessment of the company's pipeline and commercial prospects. This does not fit neatly into the earnings_release category (which typically refers to financial results) but represents a material clinical milestone disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-22T02:59:38.543602+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":1142,"accession_number":"0001437749-26-017994","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"BioCardia disclosed positive preliminary clinical trial results for CardiAMP Cell Therapy presented at a major medical conference (Euro PCR), showing safety (no major adverse cardiac events) and efficacy outcomes (179-second improvement in exercise tolerance, 82% reduction in angina episodes at six months through two-year follow-up). While this is clinical trial data rather than financial results or a traditional earnings release, the positive efficacy and safety findings for a lead therapeutic candidate are material to investors' assessment of the company's pipeline and commercial prospects. This does not fit neatly into the earnings_release category (which typically refers to financial results) but represents a material clinical milestone disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-22T02:59:38.543602+00:00","company_name":"BioCardia, Inc.","ticker":"BCDA","filing_date":"2026-05-21"}]}